Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359294 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
A Phase 1 study, sponsored by PharmaMar.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00359294 is a Phase 1 study that was terminated before completion, run by PharmaMar. The registered enrollment target is 12 participants.
The verdict
NCT00359294, a Phase 1 study, was terminated before completion, sponsored by PharmaMar.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Phase I trial, dose escalating, prospective, open-label, non-randomized, multicenter study. The purpose is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended dose (RD) of PM00104, administered intravenously over 1 hour daily for 5 days every 3 weeks (this is considered as 1 cycle) to subjects with advanced malignant solid tumors or lymphoma.
Interventions
- DRUG PM00104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359294
The ClinicalTrials.gov registry entry for NCT00359294 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PM00104 is the first listed.
NCT00359294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00359294 about?
NCT00359294 is a clinical study titled "A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma". Phase I trial, dose escalating, prospective, open-label, non-randomized, multicenter study. The purpose is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended dose (RD) of PM00104, administered intravenously over 1 hour daily for 5 days every 3 weeks (this is consider...
What is the current status of trial NCT00359294?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-05. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00359294?
The interventions under investigation include: PM00104 (DRUG).
Who is sponsoring clinical trial NCT00359294?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.